Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.32 |
| ▸ | STK4 | Q13043 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188549 | 0.94 | CDC7 (0.41) | CDC7PIM1PIM2HTR1ASLC6A2 | |
| SCHEMBL5000214 | 0.94 | CDC7 (0.39) | CDC7SCN9APIM1PIM2SLC6A2 | |
| SCHEMBL14188521 | 0.88 | FFAR4 (0.38) | CDC7SCN9APIM1PIM2PARP1 | |
| SCHEMBL14188494 | 0.88 | CDC7 (0.43) | CDC7PIM1PIM2MAP4K1NTRK1 | |
| SCHEMBL4997028 | 0.87 | CDC7 (0.50) | CDC7PIM1PIM2PARP1 | |
| SCHEMBL5000513 | 0.85 | CDC7 (0.41) | CDC7SCN9APIM1PIM2PARP1 | |
| SCHEMBL4994767 | 0.84 | PIM1 (0.38) | CDC7PIM1PIM2MAP4K1NTRK1 | |
| SCHEMBL14188431 | 0.83 | CDC7 (0.41) | CDC7SCN9APIM1PIM2PARP1 | |
| SCHEMBL14188354 | 0.82 | CDC7 (0.46) | CDC7PIM1PIM2PARP1 | |
| SCHEMBL14188385 | 0.82 | CDC7 (0.46) | CDC7PIM1PIM2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | CDC7 487/4885SCN9A 2668/4885PIM1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.